JP2009519313A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2009519313A
JP2009519313A JP2008545097A JP2008545097A JP2009519313A JP 2009519313 A JP2009519313 A JP 2009519313A JP 2008545097 A JP2008545097 A JP 2008545097A JP 2008545097 A JP2008545097 A JP 2008545097A JP 2009519313 A JP2009519313 A JP 2009519313A
Authority
JP
Japan
Prior art keywords
composition
composition according
drug
stearic acid
ethylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519313A5 (enExample
Inventor
スミス アラン
マーガレット ダイアー アン
Original Assignee
アルキメデス ディヴェロプメント リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルキメデス ディヴェロプメント リミテッド filed Critical アルキメデス ディヴェロプメント リミテッド
Publication of JP2009519313A publication Critical patent/JP2009519313A/ja
Publication of JP2009519313A5 publication Critical patent/JP2009519313A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008545097A 2005-12-15 2006-12-15 医薬組成物 Pending JP2009519313A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0525461.0A GB0525461D0 (en) 2005-12-15 2005-12-15 Pharmaceutical compositions
PCT/GB2006/004710 WO2007068948A2 (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising in particular thyroid hormones

Publications (2)

Publication Number Publication Date
JP2009519313A true JP2009519313A (ja) 2009-05-14
JP2009519313A5 JP2009519313A5 (enExample) 2009-12-24

Family

ID=35736122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545097A Pending JP2009519313A (ja) 2005-12-15 2006-12-15 医薬組成物

Country Status (8)

Country Link
US (1) US8460702B2 (enExample)
EP (1) EP1978950A2 (enExample)
JP (1) JP2009519313A (enExample)
BR (1) BRPI0619934A2 (enExample)
CA (1) CA2634006C (enExample)
GB (1) GB0525461D0 (enExample)
IL (1) IL192091A (enExample)
WO (1) WO2007068948A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
EP3125873B1 (en) * 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
CN112912067B (zh) 2018-08-31 2025-04-04 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255081A (ja) * 1991-12-30 1993-10-05 Akzo Nv 持続性放出甲状腺作用性組成物
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
JP2002526402A (ja) * 1998-10-01 2002-08-20 ノバルティス アクチエンゲゼルシャフト 新規徐放性経口製剤
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
WO2004043452A1 (en) * 2002-11-13 2004-05-27 Bracco S.P.A. 3,5,3’-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
ATE429210T1 (de) 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
KR20030011805A (ko) 2000-03-30 2003-02-11 브리스톨-마이어스스퀴브컴파니 스타부딘을 함유하는 서방성 비들렛
PT1274401E (pt) * 2000-04-10 2011-12-02 Teva Pharma Composições farmacêuticas estáveis contendo ácidos 7-substituídos-3,5-di-hidroxi-heptanóicos ou ácidos 7-substituídos-3,5-di-hidroxi-heptenóicos
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255081A (ja) * 1991-12-30 1993-10-05 Akzo Nv 持続性放出甲状腺作用性組成物
JP2002526402A (ja) * 1998-10-01 2002-08-20 ノバルティス アクチエンゲゼルシャフト 新規徐放性経口製剤
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
WO2004043452A1 (en) * 2002-11-13 2004-05-27 Bracco S.P.A. 3,5,3’-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012030514; 新・薬剤学総論 改訂第３版, 19870410, ｐｐ．２６２-２６６, 株式会社　南江堂 *
JPN6012030520; Ｚｈａｎｇ　Ｑ　ｅｔ　ａｌ．: 'Ｓｔｕｄｉｅｓ　ｏｎ　ｔｈｅ　ｃｙｃｌｏｓｐｏｒｉｎ　Ａ　ｌｏａｄｅｄ　ｓｔｅａｒｉｃ　ａｃｉｄ　ｎａｎｏｐａｒｔｉｃｌｅｓ．' Ｉｎｔ　Ｊ　Ｐｈａｒｍ． Ｖｏｌ．２００　Ｎｏ．２, 20000510, ｐｐ．１５３-１５９ *
JPN6012030521; Ｙａｎｇ　Ｚ　ｅｔ　ａｌ．: 'Ｐｒｅｐａｒａｔｉｏｎ　ｏｆ　ｃｏｍｐｌｅｘ　ｐｈｅｎｏｂａｒｂｉｔａｌ　ｆｒａｍｅｗｏｒｋ　ｓｕｓｔａｉｎｅｄ-　ｒｅｌｅａｓｅ　ｔａｂｌｅｔｓ' Ｚｈｏｎｇｇｕｏ　Ｙｉｙｕａｎ　Ｙａｏｘｕｅ　Ｚａｚｈｉ Ｖｏｌ．１８　Ｎｏ．７, 1998, ｐｐ．３１３-３１４ *
JPN6012030523; Ｓｔａｒｈａ Ｌ． ａｎｄ Ｃｈａｌａｂａｌａ Ｍ．: 'Ｏｒａｌ ｌｏｎｇ-ａｃｔｉｎｇ ｄｒｕｇｓ． ＶＩ． Ｅｆｆｅｃｔ ｏｆ ｓｔｅａｒｉｃ ａｃｉｄ ａｎｄ ｉｔｓ ｇｌｙｃｅｒｏｌ' Ｃｅｓｋｏ-Ｓｌｏｖｅｎｓｋａ Ｆａｒｍａｃｉｅ Ｖｏｌ．２０ Ｎｏ．２, 1971, ｐｐ．６０-６２ *

Also Published As

Publication number Publication date
IL192091A (en) 2012-04-30
GB0525461D0 (en) 2006-01-25
US20090130202A1 (en) 2009-05-21
IL192091A0 (en) 2008-12-29
BRPI0619934A2 (pt) 2011-10-25
EP1978950A2 (en) 2008-10-15
WO2007068948A3 (en) 2007-08-16
CA2634006C (en) 2013-07-30
US8460702B2 (en) 2013-06-11
WO2007068948A2 (en) 2007-06-21
CA2634006A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
AU2021282393B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US6426091B1 (en) Sustained-release theophylline tablet
AU760006B2 (en) Method for making granules with masked taste and instant release of the active particle
US8709996B2 (en) Pharmaceutical treatment process using chitosan or derivative thereof
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
AU2006203890A1 (en) Sustained release pharmaceutical formulations comprising ranolazine
JP2003528905A (ja) スタブジン含有持続放出性ビーズ剤
IL192091A (en) Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments
CN104997748B (zh) 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
KR20150003726A (ko) 프라수그렐을 함유하는 안정한 즉시방출형 경구 약제학적 조성물
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
WO2006130702A2 (en) Modified release formulations of antihypertensive drugs
CN113368032A (zh) 药物组合物、口服固体制剂及其制备方法和用途
US20070092568A1 (en) Galantamine compositions
WO2002034268A1 (en) Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient
RU2727721C2 (ru) Фармацевтическая композиция с замедленным высвобождением, содержащая ривастигмин
EP3184101A1 (en) Levodopa and carbidopa modified release composition
WO2003043610A2 (en) A process for manufacture of a sustained release composition containing microbe
JPH06345649A (ja) イプサピロン薬剤組成物
WO2008062426A2 (en) Formulation of benzazepine derivatives
JP2024003789A (ja) 時限放出型顆粒およびその用途
WO2016117642A1 (ja) フィルム製剤
MXPA01002821A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130709